CAP--advancing the evaluation of preclinical Alzheimer disease treatments.
CAP--advancing the evaluation of preclinical Alzheimer disease treatments.
复制标题
DOI：
10.1038/nrneurol.2015.177
复制
发表时间：
2016-01
期刊：
影响因子：
--
通讯作者：
Weninger S
中科院分区：
文献类型：
--
作者：
Reiman EM;Langbaum JB;Tariot PN;Lopera F;Bateman RJ;Morris JC;Sperling RA;Aisen PS;Roses AD;Welsh-Bohmer KA;Carrillo MC;Weninger S
如果我们要找到治疗方法来推迟，降低风险或完全预防阿尔茨海默病（AD）的临床发作，我们需要更快的方法来评估有前途的临床前AD治疗，新的方法来共同支持共同的目标，并决心加快临床前AD试验的启动和执行。在这篇文章中，我们注意到一些当前的挑战，机遇和新兴的战略，在临床前AD治疗。我们描述了阿尔茨海默氏症预防合作（CAP）-召集，协调和建立共识的倡议，以帮助利益相关者推进AD预防研究的严谨，谨慎和最大的影响，我们展示了CAP的目标和设计的新的临床前AD试验的影响。
If we are to find treatments to postpone, reduce the risk of, or completely prevent the clinical onset of Alzheimer disease (AD), we need faster methods to evaluate promising preclinical AD treatments, new ways to work together in support of common goals, and a determination to expedite the initiation and performance of preclinical AD trials. In this article, we note some of the current challenges, opportunities and emerging strategies in preclinical AD treatment. We describe the Collaboration for Alzheimer’s Prevention (CAP)—a convening, harmonizing and consensus-building initiative to help stakeholders advance AD prevention research with rigour, care and maximal impact—and we demonstrate the impact of CAP on the goals and design of new preclinical AD trials.